DOES NEBULIZED DEXAMETHASONE IMPROVE PULMONARY FUNCTION IN NEONATES?

本随机、双盲、安慰剂对照研究的具体目的是：1）测量吸入地塞米松的相对全身利用度，并评估吸入地塞米松过程中全身吸收的一致性; 2）评估和比较咨询支持的变化（通气率），吸气峰压，吸入地塞米松或静脉注射地塞米松7天疗程的呼吸机依赖性早产儿的吸入氧和分数; 3）确定全身药物暴露与静脉和吸入地塞米松后治疗参数和不良反应的改善之间的关系。 本研究入组了20例患者，但尚未分析结果。 一个重要的治疗目标是确定正在评估的一种或其他形式的治疗是否会通过最大限度地减少呼吸机引起的气压伤和氧毒性来降低支气管肺发育不良的严重程度和并发症。 先前表明地塞米松静脉输注获益的研究未设盲，因此治疗组和未治疗组之间的管理可能不相等。 尽管雾化类固醇在最大限度地减少全身类固醇暴露方面具有明显优势，但在新生儿中进行的研究尚未比较吸入类固醇的疗效、不良反应或全身吸收，也未将其结果与更常见的静脉注射地塞米松进行比较。 如果吸入类固醇导致肺功能改善与静脉类固醇相当，则风险效益比显然有利于吸入治疗。 该方案将解决早产儿护理中的这一非常重要的问题。

The specific aims of this randomized, double-blinded, placebo-controlled study are to: 1) measure the relative systemic availability of inhaled dexamethasone and assess the consistency of systemic absorption during a course of inhaled dexamethasone; 2) evaluate and compare changes in ventilatory support (rate of ventilation), peak inspiratory pressure, and fractional inspired oxygen in ventilator-dependent premature neonates receiving a 7-day course of inhaled dexamethasone or intravenous dexamethasone and; 3) define relationships between systemic drug exposure and improvements in ventilatory parameters and adverse effects after both intravenous and inhaled dexamethasone. Twenty patients have been enrolled on this study, but results have not yet been analyzed. An important treatment objective is to determine if one or the other forms of therapy being evaluated will reduce the severity and complications of bronchopulmonary dysplasia by minimizing ventilator-induced barotrauma and oxygen toxicity. Previous studies suggesting benefit from intravenous dexamethasone infusions were not blinded, and thus management may not have been equal between treated and untreated groups. Despite the apparent advantage of aerosolized steroids in minimizing systemic steroid exposure, studies conducted in neonates have not compared efficacy, adverse effects, or systemic absorption of inhaled steroids, and compared the outcome to more commonly administered intravenous dexamethasone. If inhaled steroids result in improved pulmonary function comparable to that claimed for intravenous steroids, the risk-benefit ratio would clearly favor treatment by inhalation. This protocol will address this very important issue in the care of premature neonates.